Skip to main content

Xavier Montalban Gairín

I am Chair of the Department of Neurology since 2012 and director of the Multiple Sclerosis Center of Catalonia (Cemcat) since 2007 at the Vall d'Hebron University Hospital. I am the head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Autonomous University of Barcelona (UAB) since 2006 and at the University of Vic - Central University of Catalonia (UVic-UCC) since 2021.

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

Xavier Montalban Gairín

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

I am Chair of the Department of Neurology since 2012 and director of the Multiple Sclerosis Center of Catalonia (Cemcat) since 2007 at the Vall d'Hebron University Hospital. I am the head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Autonomous University of Barcelona (UAB) since 2006 and at the University of Vic - Central University of Catalonia (UVic-UCC) since 2021.

I obtained my MD (1983) and PhD (1990) from UAB, and I completed my postgraduate fellowship at St. Thomas' Hospital and the National Hospital for Neurology and Neurosurgery in London. I obtained a Diploma in Comprehensive of Healthcare Institutions Management from ESADE (2005).

In addition to the positions I currently hold, between 2017 and 2020 I served as Professor of Medicine and Director of the Division of Neurology at the University of Toronto and as Director of the MS Center at St Michael's Hospital in the same city.

Since January 2023 I am the chair of the International Advisory Committee on Clinical Trials in Multiple Sclerosis sponsored by ECTRIMS and the National Multiple Sclerosis Society (NMSS), one of the most influential Committee in MS worldwide.

Regarding other leadership roles I am past President (2014-2016) and current Honorary Member of the Council of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). I’m also Board Member of the European Charcot Foundation, as well as serving on numerous local, national and international boards and committees.

My scientific production acrues over 800 scientific papers published in peer-reviewed journals, amounting? more than 52,000 citations and a Scopus H-Index of 101. Over the last consecutive five years I have ranked among the Clarivate most cited researchers.

I have been the Principal Investigator (PI) or Collaborator in more than 35 competitive Projects and have participated as PI in more than 150 clinical trials.

Of Note, I am the recipient of the 2022 John Dystel Prize for MS Research, awarded jointly by the National Multiple Sclerosis Society (NMSS) and the American Academy of Neurology (AAN). I’m the winner of the 2023 Charcot Award granted by the Multiple Sclerosis International Federation (MSIF), which recognises a lifetime of achievement in outstanding research into understanding and treating MS.

Projects

Sol·licitud Juan Rodés

IP: Xavier Montalban Gairín
Collaborators: Angela Vidal Jordana, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 135000
Reference: JR16/00024
Duration: 01/01/2017 - 21/04/2020

Investigation of the role of female hormonal factors in risk and prognosis of multiple sclerosis

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: ECTRIMS
Funding: 25000
Reference: ECTRIMS_CTFP2014
Duration: 02/11/2015 - 02/05/2016

Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

IP: Xavier Montalban Gairín
Collaborators: Ana Isabel Guerrero Perez, Carlos Nos Llopis, Gabriel Ig Camiña Rodríguez, Ana Zabalza de Torres, Luciana Midaglia Fernandez
Funding agency: The Innovative Medicines Initiative
Funding: 552235
Reference: RADAR_IMI2015
Duration: 01/04/2016 - 31/03/2022

Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC)

IP: Xavier Montalban Gairín
Collaborators: Susana Otero Romero, Carlos Nos Llopis, Sunny Malhotra Sareen, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Margarida Capell Maymo, Silvia Soler García, Carmen Tur Gomez, Jordi Barquinero Mañez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Sergio Vergara Ruiz, Luciana Midaglia Fernandez, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Mireia Castillo Juarez, Nicolás Miguel Fissolo, Georgina Arrambide García
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 50000
Reference: 2014 SGR 1082
Duration: 01/01/2014 - 31/12/2016

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Roser Navarro García

Roser Navarro García

Infectious Diseases
Read more
Mª Carmen López  Arribas

Mª Carmen López Arribas

Research technician
Molecular Medical Imaging
Read more
Jesús Francisco Lopez Lozano

Jesús Francisco Lopez Lozano

Read more
Jorge Serra Pueyo

Jorge Serra Pueyo

Main researcher
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.